Sounds like an opportunity for greater partnership/collaboration to optimize combination bridging and/or salvage strategies ILROG Team ASTRO Chelsea C Pinnix MD PhD Joachim (Achy) Yahalom Bouthaina Dabaja MD Nick Figura, MD Michael Jain Jeff Ryckman

#medstudents interested in #radonc - check out our ACROresident podcast 🎙 on preparing for residency interview for #MATCH2023 !

🙏🏽 to everyone who submitted ❓

alexis schutz Cyrus Washington, MD
Inside The Match

Jeff Ryckman 5’UTR David Hodgson and when it does not work...can we have some RT so the CAR-T gets a boost please

5’UTR David Hodgson It’s easier to corner the market when RT is thrown out of the equation. It behooves the industry to forego the 5-10% PFS advantage with RT and sweep salvage Tx toxicity data under the rug 💸

Blows my mind how many patients get to CAR-T without ever having seen RT 🤯

1/n Both PPS exemption, and, much more substantially from a discretionary spending perspective, the 340B program are well-intentioned statutory schemes that may need updating.

📢 #ACRO2023 News: Stephen Hahn, M.D. will be kicking off The Radiation Oncology Summit with a keynote discussion on 'FDA Lessons Learned from the Pandemic: Accelerating Innovation and Reimagining Health.' Register today for early bird pricing at acro.org/Annual_Meeting!

In the latest ACRO Podcast, ACRO Resident Committee members Drs. Niema Razavian, Alexis Schutz, and Cyrus Washington provide tips for #radonc residency program interviews. Access the content: youtu.be/1yR5y4ZMwy8

Million dollar question right there!

Hats off to David Hodgson and COG for setting the bar and appropriately valuing RT in the treatment of Hodgkins Lymphoma

Unlike ECHELON-1🙄

Seems like adult HL trials have something to learn from COG! 👏 #radonc #hemeonc #medonc #medtwitter

#CALGB50801 : Omitting RT in bulky (>10 cm or 1/3 the maximum intrathoracic diameter) early-stage cHL

🚫 Omits RT at expense of 2 addnl cycles of ABVD.
🚫 Does not discuss the degree of CT-based residual.
🚫 Utilized outdated RT methods (IFRT) in SER.
1/3 pubmed.ncbi.nlm.nih.gov/36269899/

In the latest ACRO Podcast, the ACRO Resident Subcommittee Chairs discuss the overall mission of the ACRO Resident Committee and the focus and benefits of each subcommittee they lead. Check it out: youtu.be/P7hZR-svbfg

Dhruv Srinivasachar MD (he/el/ele.) Harry Thomas The diff between NZ and USA is vast - this wouldn't happen in NZ

Big pharma doesnt have to endure the same level of oversight in the US (highest drug spending per capita) as it does in NZ (lowest drug spending per capita)
Jordan Harbinger John Abramson
podcasts.apple.com/us/podcast/the…

Milan Hora Sarah P. Psutka MD MS Arnaud Méjean, MD, PhD Jeff Ryckman In oncology, HR < 0.5 w ARR > 10% would be incredible.

The best HR seen in all RCTs of local tx is ~0.8, but most are ~1.0 (ie, local tx does not help).

The HR in this study is 0.33, 95% CI 0.24–0.45, ARR > 50%.

This paragraph explains why:

Our friends QuadShot News have new content! Today- FLASH proton therapy talk; 11/2- new AI based prostate cancer risk stratification tool; 11/4- HN004 results evaluating role of cetuximab vs durvalumab w/ radiation in cisplatin unfit patients. Access at acro.org/acropolis!

Milan Hora Sarah P. Psutka MD MS Arnaud Méjean, MD, PhD Jeff Ryckman One way to evaluate for immortal time bias (which is seen in retrospective comparative effectiveness research) is to look at the KM curves. If one curve has no events for prolonged time, the pts are 'immortal' during this time.